ZURA Stock Forecast & Price Target

Zura Bio is well positioned because tibulizumab’s dual IL-17A x BAFF mechanism offers a differentiated, orthogonal approach in autoimmune disease areas where monotherapies may have reached an efficacy ceiling. The company has multiple near-term catalysts, including the 4Q26 HS readout, 1H27 SSc data, and a by-year-end-2026 PMR Phase 2 start, while 2Q26 cash of $205.1MM and a projected runway through at least YE28 reduce financing risk. PMR adds a sizable, underpenetrated opportunity with roughly 700K U.S. patients, only one approved biologic, and projected 2035E worldwide sales of $1.6B for the indication.

Zura Bio is exposed to substantial fundamental risk because its outlook depends heavily on tibulizumab, and any clinical or regulatory failure in target indications would materially impair the company’s core value proposition. The lead programs may not prove efficacious, and safety signals could halt development, which is especially problematic for a clinical-stage biotech with no diversified commercial base to offset setbacks. Even if development advances, the company still faces the possibility of missing sales estimates, commercial competition from current and future therapies, and manufacturing or shipment disruptions that could further weaken execution.